BiTE-EV for relapsed or hard-to-treat B-cell leukemia
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new immunotherapy drug called BiTE-EV for people with B-cell acute lymphoblastic leukemia that has come back after treatment or is not responding well. The drug is designed to help your immune system find and kill cancer cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have B-cell acute lymphoblastic leukemia that has returned after CAR-T treatment or transplant, or cannot be treated with CAR-T because your T cells aren't available.
- Your leukemia cells have a protein called CD19 on their surface.
- You are between 18 and 70 years old.
- Your expected survival is more than 3 months.
- You are in fairly good health (able to do daily activities) and your heart, lungs, kidneys, and liver are working well enough.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune cell therapy (CAR-T) that targets two proteins on cancer cells—CD19 and CD22—to treat lymphoma or leukemia that has come back or not responded to standard treatment. It aims to see if this two-target approach works better.
This trial tests a new treatment called B019 for people whose B-cell acute lymphoblastic leukemia has come back or not responded to standard therapy. The treatment targets specific proteins on the cancer cells to help your immune system fight the leukemia.
This trial tests whether giving you a special kind of immune cell, called a CAR T cell, can help fight your B-cell leukemia or lymphoma that has come back or not gone away with standard treatments. The cells are made from your own blood and designed to attack the cancer cells that carry a marker called CD19.
This trial tests a new CAR T-cell therapy (KITE-753) for adults with B-cell acute lymphoblastic leukemia (ALL) that has come back or not responded to previous treatments. The therapy uses your own immune cells, modified to find and attack leukemia cells, and may offer a new option when standard treatments have stopped working.
This trial tests a new type of CAR T-cell therapy that targets two proteins on cancer cells (CD20 and CD19) for B-cell cancers like lymphoma and leukemia that have come back or not responded to other treatments. It might help you if your cancer hasn't been controlled by standard options.
This trial tests a new type of immune cell therapy (CAR-T) that uses donor cells to target and kill leukemia cells. It is for adults with B-cell acute lymphoblastic leukemia that has not responded to at least two prior treatments.
Hear when a new Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.